Montreal Pharma CEO and Accomplices Accused of Stock Market Manipulation
- A Montreal pharmaceutical company CEO and three associates have been accused of market manipulation in a scheme that allegedly promised participants they could each make $1 million quickly,...
- The allegations center on fraudulent stock promotion practices involving a Montreal-based pharmaceutical firm, though the company’s name was not disclosed in the initial report.
- The phrase “On peut faire chacun 1 M$ rapidement” — translated as “You can each make $1 million quickly” — was cited as part of the alleged promotional...
A Montreal pharmaceutical company CEO and three associates have been accused of market manipulation in a scheme that allegedly promised participants they could each make $1 million quickly, according to a report by TVA Nouvelles.
The allegations center on fraudulent stock promotion practices involving a Montreal-based pharmaceutical firm, though the company’s name was not disclosed in the initial report. The accusations were made public through a Google News discovery feed dated April 17, 2026, which highlighted the TVA Nouvelles story as a recent development in Quebec’s ongoing scrutiny of market integrity.
The phrase “On peut faire chacun 1 M$ rapidement” — translated as “You can each make $1 million quickly” — was cited as part of the alleged promotional language used to attract investors, suggesting a coordinated effort to inflate interest in certain securities through misleading financial promises.
While the TVA Nouvelles report did not specify the regulatory body involved, similar cases in Quebec have typically been pursued by the Autorité des marchés financiers (AMF), the province’s securities regulator. Past AMF actions have targeted pump-and-dump schemes, false representations of company value, and coordinated trading designed to manipulate stock prices.
In August 2017, the AMF fined Montreal resident Jean-François Amyot $11.2 million and sentenced him to a three-month intermittent jail term for his role in a pump-and-dump scheme involving five companies. Amyot and associates were found to have falsely portrayed the value of those companies to trick investors into purchasing their stocks, resulting in over $18.2 million in combined penalties for individuals and corporations involved.
More recently, in December 2025, Quantum BioPharma filed a $700 million lawsuit against Canada’s two largest banks, CIBC and RBC, alleging widespread stock spoofing — a form of market manipulation involving the placement and rapid cancellation of fake orders to mislead other traders about supply and demand. The allegations were featured in a nationally broadcast investigative series by CTV’s W5, which examined claims of illegal trading practices affecting Canadian markets.
Stock spoofing, as described in regulatory and legal contexts, involves creating artificial market activity to deceive other participants, often to profit from resulting price movements. Both pump-and-dump schemes and spoofing are prohibited under Canadian securities law and have been subject to enforcement actions by federal and provincial regulators.
The TVA Nouvelles report contributes to a pattern of regulatory and media attention on market manipulation in Quebec and across Canada, particularly involving penny stocks and speculative investments where information asymmetry can be exploited. As of the report’s publication, no charges had been formally laid, and the accused individuals had not entered pleas in court.
News Directory 3 will continue to monitor developments in this case through official regulatory channels and verified reporting as more information becomes available.
